Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (COVID-19)

Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm.

Study Overview

• Status: Terminated
• Conditions: Covid19
• Intervention / Treatment: Biological: Placebo; Biological: SARS-CoV-2 vaccine

Detailed Description

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm. Each dose of vaccine will be defined as a cohort in itself, with vaccine administration to 20 participants and placebo administration to 5 participants. After completion of low-dose group, decision of switch to high-dose will be taken by the Independent Data Monitoring Committee and will continue accordingly.

In the study, 50 healthy participants of 18-45 years of age will be recruited.

All injections will be done subcutaneously.

Injections will be administered at 1 and 21 days.

The participants will be followed for 6 months and the study will be completed in 12 months.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 1

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey, 06800
    • Ankara City Hospital Phase I Drug Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

To be eligible for the study, each participant must satisfy all the following criteria:

1. Healthy participants between 18-45 years of age,
2. Sign an informed consent document,
3. Negative immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for COVID-19,
4. Negative quantitative polymerase chain reaction (qPCR) SARS-CoV-2 results of nasopharyngeal/sputum samples,
5. Able to comply with the study protocol during the study period,
6. Negative tests for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV),
7. Body temperature <37.2 C and no signs of active infection,
8. Body mass index 18-35 kg/m2,
9. Normal laboratory levels of whole blood count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, urea, creatinine, and fasting blood glucose, or abnormal finding detected in any laboratory parameter which is not greater than Grade 1 according to the investigator's evaluation,
10. Good general health (no known disease in the history and physical examination within 14 days prior to the enrolment),
11. Female and male participants who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination,

Exclusion Criteria:

Participants with any of the following criteria will be excluded:

1. History of seizure, encephalopathy, or psychosis,
2. History of allergic reactions to any known vaccine or to any component of the study vaccine,
3. Pregnant, breastfeeding, or positive pregnancy test or planning to conceive within 6 months,
4. History of SARS-CoV-2 infection,
5. Severe cardiovascular disorders (arrhythmia, conduction disorders, history of myocardial infarction, uncontrolled hypertension),
6. Severe chronic disorders (asthma, diabetes mellitus, thyroid disorders…etc),
7. Congenital or acquired angioedema,
8. Diagnosis of immunodeficiency,
9. Diagnosis of bleeding diathesis,
10. Use of immunosuppressive treatment, anti-allergic treatment, cytotoxic treatment, inhaler corticosteroids (allergic rhinitis or topical steroid ointments are excluded),
11. Those who received blood and blood product transfusions in the last 6 months,
12. Those on any vaccine program or experimental medication within 1 month prior to the study,
13. History of any vaccination against SARS-CoV-2 within 1 month prior to the study,
14. Use of active tuberculosis treatment,
15. History of addictive drug use,
16. History of alcohol abuse and/or history of alcohol intake more than 2 units per day or 10 units per week and/or positive breath alcohol test (one unit of alcohol equals to 250 mL beer, 125 mL wine or 25 mL whiskey),
17. According to the investigator's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the patient's compliance with the study will be excluded from the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low-Dose Group (Group A); 20 participants will receive 10 µg-3M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine	Biological: SARS-CoV-2 vaccine; Adjuvanted inactivated vaccine
Experimental: High-Dose Group (Group B); 20 participants will receive 20 µg-6M inactivated virus + 1 mg Al(OH)3 + 300 µg CpGODN adjuvanted vaccine	Biological: SARS-CoV-2 vaccine; Adjuvanted inactivated vaccine
Placebo Comparator: Placebo Group; 10 participants will receive 1 ml of 0.9% sodium chloride (NaCl)	Biological: Placebo; 0.9% NaCl

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Unsolicited local and systemic adverse events (AEs)	Frequency of local and systemic AEs in all dosage groups	28 days
Acute adverse events (AEs)	Frequency of acute adverse events in all dosage groups	24 hours
Solicited local and systemic adverse events (AEs)	Frequency of local and systemic AEs in all dosage groups	15 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Neutralizing antibody response	Immunogenicity response by measuring neutralizing antibody titer (anti-spike and anti-RBD) developed against SARS-CoV-2 (by ELISA)	Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration.
Cellular immune response	Interferon-γ (IFN-γ) positive cell level (by ELISPOT)	Before first dose administration, on Day 21-28-35 and Month 3 and Month 6 after first dose administration.

Collaborators and Investigators

• Sponsor: Osman ERGANIS, PhD, Prof
• Collaborators: The Scientific and Technological Research Council of Turkey; MonitorCRO; VETAL Inc.

Study record dates

Study Major Dates

• Study Start (Actual): April 25, 2021
• Primary Completion (Actual): September 5, 2021
• Study Completion (Actual): September 5, 2021

Study Registration Dates

• First Submitted: April 26, 2021
• First Submitted That Met QC Criteria: April 26, 2021
• First Posted (Actual): April 29, 2021

Study Record Updates

• Last Update Posted (Actual): April 18, 2023
• Last Update Submitted That Met QC Criteria: April 17, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: SARS-CoV-2; Adjuvanted inactivated vaccine
• Other Study ID Numbers: ISV2AOH3ODN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No